Brief: ESSA Pharma Announces Clinical Trial Support Agreement With Janssen To Evaluate EPI-7386 Combinations In Patients With Prostate Cancer

ESSA Pharma

12/04/2023 12:48

April 12 (Reuters) - ESSA Pharma Inc  EPIX.O :
    * ESSA PHARMA ANNOUNCES CLINICAL TRIAL SUPPORT AGREEMENT
WITH
JANSSEN TO EVALUATE EPI-7386 COMBINATIONS IN PATIENTS WITH
PROSTATE CANCER
    * ESSA PHARMA INC: ENTERED INTO A CLINICAL TRIAL SUPPORT
AGREEMEN
WITH JANSSEN RESEARCH & DEVELOPMENT, LLC
    * ESSA PHARMA INC: ESSA WILL RETAIN ALL RIGHTS TO EPI-7386
    * ESSA PHARMA: WILL CONDUCT PHASE 1 TRIAL EVALUATING SAFETY,
PHARMACOKINETICS, DRUG-DRUG INTERACTIONS, AND PRELIMINARY
ANTI-TUMOR ACTIVITY OF EPI-7386
    * ESSA PHARMA INC: JANSSEN WILL SUPPLY APALUTAMIDE AND
ABIRATERONE
ACETATE FOR TRIAL

Source text for Eikon:  ID:nCNWchGcga 
Further company coverage:  EPIX.O 

 ((Reuters.Briefs@thomsonreuters.com;))